Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled study of subcutaneous tanezumab for opioid-treated cancer pain due predominantly to bone metastases
MOH_2018-02-26_002214Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Apr 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tanezumab in bone metastases (3 arms), sponsored by Pfizer. Primary endpoint: Change from baseline to week 8 in average daily pain intensity. Started Apr 2017; status: recruiting.
02
Drugs
tanezumab
03
Conditions
bone metastases
Beyond the preview
Go deeper on MOH_2018-02-26_002214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-02-26_002214.